{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:39:01Z","timestamp":1791142741620,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.drudis.2014.09.022","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T20:12:48Z","timestamp":1412367168000},"page":"262-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders?"],"prefix":"10.1016","volume":"20","author":[{"given":"Bart L.","family":"Loeys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2014.09.022_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCRESAHA.113.300675","article-title":"Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-beta signaling and vascular smooth muscle cell contractility","volume":"113","author":"Gillis","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2014.09.022_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.022_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1172\/JCI200420641","article-title":"Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome","volume":"114","author":"Judge","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2014.09.022_bib0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2014.09.022_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.drudis.2014.09.022_bib0030","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI200422715","article-title":"TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome","volume":"114","author":"Ng","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2014.09.022_bib0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states","volume":"13","author":"Cohn","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1126\/science.1192152","article-title":"Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism","volume":"332","author":"Habashi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.drudis.2014.09.022_bib0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.1192149","article-title":"Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice","volume":"332","author":"Holm","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.drudis.2014.09.022_bib0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nature10145","article-title":"Lessons on the pathogenesis of aneurysm from heritable conditions","volume":"473","author":"Lindsay","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.09.022_bib0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ng1511","article-title":"A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2","volume":"37","author":"Loeys","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2014.09.022_bib0070","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJMoa055695","article-title":"Aneurysm syndromes caused by mutations in the TGF-beta receptor","volume":"355","author":"Loeys","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0075","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ng.2349","article-title":"Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm","volume":"44","author":"Lindsay","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2014.09.022_bib0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ng.744","article-title":"Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis","volume":"43","author":"van de Laar","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2014.09.022_bib0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/jmedgenet-2011-100382","article-title":"Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome","volume":"49","author":"van de Laar","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.drudis.2014.09.022_bib0090","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI69666","article-title":"Angiotensin II-dependent TGF-beta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis","volume":"124","author":"Gallo","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2014.09.022_bib0095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jb\/mvs089","article-title":"Matrix control of transforming growth factor-beta function","volume":"152","author":"Horiguchi","year":"2012","journal-title":"J. Biochem."},{"key":"10.1016\/j.drudis.2014.09.022_bib0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.hco.0000139723.49937.43","article-title":"Timing of aortic surgery in the Marfan syndrome","volume":"19","author":"Braverman","year":"2004","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0022-4804(89)90197-2","article-title":"Propranolol stimulates the crosslinking of matrix components in skin from the aneurysm-prone blotchy mouse","volume":"46","author":"Brophy","year":"1989","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.drudis.2014.09.022_bib0110","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","article-title":"Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome","volume":"330","author":"Shores","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0120","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1161\/CIR.0b013e3181d47d48","volume":"121","author":"Hiratzka","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.09.022_bib0125","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0130","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1056\/NEJMe0804008","article-title":"A small molecule for a large disease","volume":"358","author":"Pyeritz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","article-title":"Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study","volume":"88","author":"Chiu","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.drudis.2014.09.022_bib0140","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.amjcard.2013.06.019","article-title":"Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome","volume":"112","author":"Pees","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0145","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2014.09.022_bib0150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.09.022_bib0155","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2125.2011.03929.x","article-title":"Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine","volume":"72","author":"Li-Wan-Po","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/HCO.0b013e328353bc4f","article-title":"Which, if any, antihypertensive agents cause cancer?","volume":"27","author":"Singh","year":"2012","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0170","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/msj.20200","article-title":"Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients","volume":"77","author":"Cook","year":"2010","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0175","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1291\/hypres.31.1549","article-title":"Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan","volume":"31","author":"Yin","year":"2008","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.drudis.2014.09.022_bib0180","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jama.298.13.1539","article-title":"Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial","volume":"298","author":"Ahimastos","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2014.09.022_bib0185","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1161\/CIRCULATIONAHA.105.601674","article-title":"Induction of macrophage chemotaxis by aortic extracts of the mgR Marfan mouse model and a GxxPG-containing fibrillin-1 fragment","volume":"114","author":"Guo","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.09.022_bib0190","doi-asserted-by":"crossref","first-page":"e20138","DOI":"10.1371\/journal.pone.0020138","article-title":"Induction of macrophage chemotaxis by aortic extracts from patients with Marfan syndrome is related to elastin binding protein","volume":"6","author":"Guo","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2014.09.022_bib0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/hmg\/dds439","article-title":"Antagonism of GxxPG fragments ameliorates manifestations of aortic disease in Marfan syndrome mice","volume":"22","author":"Guo","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2014.09.022_bib0200","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1161\/CIRCRESAHA.108.174367","article-title":"Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9","volume":"102","author":"Chung","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2014.09.022_bib0205","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jvs.2007.09.016","article-title":"Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome","volume":"47","author":"Xiong","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.drudis.2014.09.022_bib0210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtcvs.2009.10.039","article-title":"Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome","volume":"140","author":"Yang","year":"2010","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.drudis.2014.09.022_bib0215","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0741-5214(00)90163-0","article-title":"Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms","volume":"31","author":"Curci","year":"2000","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.drudis.2014.09.022_bib0220","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1067\/mva.2001.117891","article-title":"Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study","volume":"34","author":"Mosorin","year":"2001","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.drudis.2014.09.022_bib0225","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1161\/CIRCULATIONAHA.110.012187","article-title":"Pravastatin reduces Marfan aortic dilation","volume":"124","author":"McLoughlin","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.09.022_bib0230","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.mehy.2009.04.058","article-title":"A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes)","volume":"73","author":"Sorice","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.drudis.2014.09.022_bib0235","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"Lacro","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2014.09.022_bib0240","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2459\/JCM.0b013e3283232a45","article-title":"Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations","volume":"10","author":"Gambarin","year":"2009","journal-title":"J. Cardiovasc. Med."},{"key":"10.1016\/j.drudis.2014.09.022_bib0245","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acvd.2010.04.008","article-title":"Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome","volume":"103","author":"Detaint","year":"2010","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.drudis.2014.09.022_bib0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-11-3","article-title":"Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial","volume":"11","author":"Radonic","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.drudis.2014.09.022_bib0255","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.recesp.2011.02.009","article-title":"Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome","volume":"64","author":"Forteza","year":"2011","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0260","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijcard.2010.12.070","article-title":"The Ghent Marfan Trial \u2013 a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with beta-blockers","volume":"157","author":"Moberg","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.drudis.2014.09.022_bib0265","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/1745-6215-14-408","article-title":"A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol","volume":"14","author":"Mullen","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.drudis.2014.09.022_bib0270","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0895-7061(99)00152-1","article-title":"Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells","volume":"Feb; 13","author":"Fukuda","year":"2000","journal-title":"Am J Hypertens"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614003882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614003882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:22:23Z","timestamp":1761222143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644614003882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1359644614003882"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2014.09.022","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2014.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}